GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Opthea Limited
Opthea is an Australian biotech company developing drugs for the treatment of eye diseases. Its stock price is driven by clinical trial results. The chart reflects hopes that its drug will become a new standard of care in ophthalmology.
Share prices of companies in the market segment - Pharma eyes
Opthea Limited is an Australian biopharmaceutical company developing treatments for retinal diseases such as wet macular degeneration. We've categorized it as "Pharma: Eye." The chart below shows how investors view the ophthalmology sector.
Broad Market Index - GURU.Markets
Opthea Limited is an Australian biopharmaceutical company developing treatments for retinal diseases such as wet macular degeneration. We've categorized it as "Pharma: Eye." The chart below shows how investors view the ophthalmology sector.
Change in the price of a company, segment, and market as a whole per day
OPT - Daily change in the company's share price Opthea Limited
For Opthea Limited, a company developing eye treatments, daily volatility reflects sensitivity to clinical trial data. This metric is an important element for assessing risk in this competitive field.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Opthea Limited is an Australian biopharmaceutical company developing drugs for the treatment of retinal diseases. Ophthalmology is a highly specialized and competitive field. The chart below shows volatility in this sector, allowing you to assess how OPT shares react to industry news.
Daily change in the price of a broad market stock, index - GURU.Markets
Opthea is an Australian biotech company specializing in eye diseases. Its shares bring the dynamism of this cutting-edge medical field to the US market, adding an international dimension to the overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Opthea Limited
For Opthea Limited, the year-over-year trend is a story about the development of its drug for treating retinal diseases. Its 12-month market capitalization is entirely dependent on data from Phase III clinical trials. The success of its lead candidate, which could offer better efficacy than existing blockbusters, will be a breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Opthea, a late-stage biotech company, develops drugs for the treatment of eye diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this vast but competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Opthea, an Australian biopharmaceutical company developing a drug to treat retinal diseases, is a competitor to giants Regeneron and Roche. Its year-over-year market capitalization reflects expectations for the results of its key clinical trials.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Opthea Limited
Opthea is a late-stage Australian biopharmaceutical company. Its monthly performance is entirely dependent on the results of its key clinical trials. The data on its drug for treating retinal diseases is the highlight.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Opthea is an Australian biopharmaceutical company developing a new drug for the treatment of retinal diseases such as wet age-related macular degeneration. The chart below shows the overall dynamics of the ophthalmic pharmaceutical sector, a large and competitive market where new therapies are in demand.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotech stocks often live in a world of their own, where news about clinical trials trumps overall market trends. The chart below shows the pulse of the broader market. Does Australia's Opthea Limited move in sync with the broader market, or do its R&D developments create a completely separate story?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Opthea Limited
Opthea, an Australian biotech company developing drugs to treat eye diseases, has been reflecting hope in ophthalmology each week. Its stock price is responding to clinical trial data from its drug, which could become a new standard of treatment for age-related macular degeneration.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Opthea Limited is an Australian biotech company developing therapeutics for retinal diseases. This chart compares its data-driven performance with the global ophthalmology sector and provides insight into the market's perception of its chances of success in this large market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Opthea is a biopharmaceutical company focused on eye diseases. Its success depends on the results of clinical trials. This chart will help you understand: does Opthea live in its own world of scientific news, or are the overall market conditions and risk appetite actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
OPT - Market capitalization of the company Opthea Limited
Opthea's market capitalization chart tells the story of an Australian biotech company developing a drug to treat retinal diseases. Its volatile dynamics reflect investors' assessment of late-stage clinical trial data. Its trajectory reflects the company's hopes for a new standard of treatment that can compete with blockbusters from the giants.
OPT - Share of the company's market capitalization Opthea Limited within the market segment - Pharma eyes
Opthea Limited is an Australian biotech company developing therapies for eye diseases. Its share of the ophthalmology market cap reflects the global expectations for its lead drug. The chart shows how its share price changes as it approaches potential market launch.
Market capitalization of the market segment - Pharma eyes
Opthea is an Australian biotech company developing drugs to treat retinal diseases. The chart below shows the overall market capitalization of the ophthalmology sector. Its dynamics provide the backdrop against which Opthea is attempting to bring to market a new standard of treatment for one of the leading causes of blindness.
Market capitalization of all companies included in a broad market index - GURU.Markets
Opthea is an Australian biotech company developing therapies for retinal diseases. Its market cap represents hope for millions of people suffering from age-related macular degeneration. Its performance on the overall chart reflects how global science is tackling one of the leading causes of blindness.
Book value capitalization of the company, segment and market as a whole
OPT - Book value capitalization of the company Opthea Limited
Opthea's balance sheet represents its capital invested in late-stage clinical trials of a new drug for the treatment of wet age-related macular degeneration. This represents a real, scientific foundation for combating one of the leading causes of blindness. How has this Australian biotech asset changed? The chart below shows its dynamics.
OPT - Share of the company's book capitalization Opthea Limited within the market segment - Pharma eyes
Opthea Limited is an Australian company developing a drug to treat retinal diseases. The chart shows the share of its R&D assets, reflecting the physical foundation of its work on one of the leading causes of blindness.
Market segment balance sheet capitalization - Pharma eyes
Opthea, a late-stage biopharmaceutical company, has a relatively lightweight model. It focuses on developing its drug and outsourcing manufacturing. The BCap_Seg chart for the biotech sector serves as a backdrop, showing the varying levels of capital intensity.
Book value of all companies included in the broad market index - GURU.Markets
Opthea's book value is its intellectual property, which is used to develop a drug for treating retinal diseases such as wet age-related macular degeneration. The company's assets are the capitalized results of years of research. The chart below shows how these research assets are valued.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Opthea Limited
Opthea Limited is an Australian biotech company developing eye treatments. Its balance sheet represents R&D expenses. Its market capitalization represents investors' hopes for the success of its key drug in the global market. The chart shows the volatility of its valuations depending on clinical trial news.
Market to book capitalization ratio in a market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company developing novel therapies for retinal diseases, the leading cause of blindness in the elderly. Its valuation is heavily dependent on the success of its key clinical trials.
Market to book capitalization ratio for the market as a whole
Opthea Limited, a biopharmaceutical company specializing in eye diseases, invests in research. Its market valuation reflects investor expectations for the success of future drugs. This chart shows how the biotech innovation premium differs from the market average.
Debts of the company, segment and market as a whole
OPT - Company debts Opthea Limited
Opthea Limited, an Australian late-stage biotech developing a drug to treat retinal diseases, is using capital to conduct large-scale international clinical trials. This chart shows how the company is raising significant funds to compete in the vast ophthalmology market.
Market segment debts - Pharma eyes
Opthea is a late-stage Australian biotech developing a drug to treat retinal diseases. Funding large, final clinical trials requires significant resources. This chart shows how the company is raising capital, potentially through partnerships and equity financing, to complete its development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Opthea Limited
Opthea Limited is an Australian biotechnology company developing a drug to treat retinal diseases. Global clinical trials require enormous expenditures. This chart shows the company's reliance on debt to finance its large-scale research, which is a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Pharma eyes
Opthea is an Australian biotech company developing drugs to treat retinal diseases, a leading cause of blindness in the elderly. This chart shows how aggressively the sector uses debt for R&D, providing context for how Opthea finances its costly international clinical trials.
Debt to book value of all companies in the market
Opthea Limited, an Australian biopharmaceutical company developing therapies for eye diseases, is conducting expensive global clinical trials. This chart shows the overall debt burden in the market. It allows one to assess how the company finances its international R&D projects and how its debt strategy is typical for the biotech sector.
P/E of the company, segment and market as a whole
P/E - Opthea Limited
Opthea Limited is a biopharmaceutical company developing new treatments for retinal diseases, such as wet age-related macular degeneration. This chart shows how investors value its lead drug. The valuation depends entirely on the results of late-stage clinical trials and its potential in the vast ophthalmology market.
P/E of the market segment - Pharma eyes
This industry chart for biopharmaceutical companies serves as a benchmark for Opthea. It reflects the overall sentiment in the sector. Comparisons with it help understand how the market views Opthea's development in the field of retinal diseases and whether it believes it can compete with blockbuster drugs from major pharma companies.
P/E of the market as a whole
Opthea is an Australian biopharmaceutical company developing drugs for the treatment of eye diseases. Its valuation is entirely dependent on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Opthea Limited
The chart for Opthea Limited, a biopharmaceutical company developing drugs for retinal diseases, shows market expectations for its lead drug candidate. It reflects investors' belief that its drug could become a new standard of care for millions of patients.
%20P%2FE%20Opthea%20Limited&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Opthea-Limited&v=1772551614543 "Chart of the company's future (projected) P/E Opthea Limited")
Future (projected) P/E of the market segment - Pharma eyes
Opthea is an Australian biopharmaceutical company developing a new drug for the treatment of wet age-related macular degeneration (AMD), a leading cause of blindness in the elderly. The chart shows industry forecasts. This helps assess how the market perceives Opthea's chances of competing with blockbusters from Regeneron and Roche in the vast AMD treatment market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772551614570 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Opthea Limited is an Australian biopharmaceutical company developing drugs for eye diseases and listed in the US. Its valuation depends on global investor interest in its developments. This chart, reflecting sentiment in the world's largest market, influences the availability of capital for foreign biotech companies.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772551614610 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Opthea Limited
Opthea Limited is an Australian biopharmaceutical company developing therapies for retinal diseases. While in late-stage clinical trials, it is suffering significant losses. This chart illustrates the global effort and enormous costs required to create a new standard of care for millions of patients.
Profit of companies in the market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company developing a new therapy for retinal diseases that lead to vision loss. This chart, showing ophthalmology profitability, illustrates the size of the age-related macular degeneration treatment market. Their drug targets two key factors in vascular growth, which could provide an advantage.
Overall market profit
Opthea Limited is an Australian biopharmaceutical company developing a new therapy for retinal diseases that lead to blindness. This is a huge market, and the company's success depends on the results of late-stage clinical trials. This gross profit chart reflects the global investment climate, which is important for raising funds for such large projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Opthea Limited
Opthea Limited is an Australian biopharmaceutical company developing a new drug for the treatment of wet age-related macular degeneration, the leading cause of blindness in the elderly. This graph reflects analysts' expectations for the success of the final phase of clinical trials, which is a bet on a new standard of treatment in a multi-billion dollar market.
%20profit%20of%20the%20company%20Opthea%20Limited&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Opthea-Limited&v=1772551614937 "Graph of future (projected) profit of the company Opthea Limited")
Future (predicted) profit of companies in the market segment - Pharma eyes
Opthea Limited is an Australian biopharmaceutical company in late-stage development of a new drug for the treatment of retinal diseases such as wet age-related macular degeneration. The company's future depends on the success of its clinical program. This chart for the pharmaceutical sector illustrates general expectations for innovation in ophthalmology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772551614945 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Opthea Limited is a biopharmaceutical company developing treatments for retinal diseases. Its value is determined by the potential of its lead drug. The overall economic sentiment reflected in this forecast influences the valuation of the entire biotech industry and investor decisions.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772551615017 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Opthea Limited
Opthea Limited is a biopharmaceutical company developing a new drug for the treatment of retinal diseases such as wet age-related macular degeneration. The chart shows an estimate of its future potential. Investors are betting that its drug will be a breakthrough in ophthalmology and generate billions in sales.
P/S market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company developing new treatments for retinal diseases, the leading cause of blindness. The company's valuation is based on the future potential of its key drug. This chart, which displays the average valuation in biotech companies, helps understand how the market views Opthea's chances of success in the vast ophthalmology market.
P/S of the market as a whole
Opthea is an Australian biopharmaceutical company developing a new drug for the treatment of wet age-related macular degeneration, the leading cause of blindness in the elderly. This chart, which reflects market revenue estimates, is a measure of Opthea's hopes. It demonstrates the enormous value investors place on this potential ophthalmology blockbuster.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Opthea Limited
Opthea is an Australian biopharmaceutical company developing therapies for retinal diseases such as wet age-related macular degeneration. Its drug could become a new standard of care. This chart reflects investor expectations for the success of its clinical programs and future commercial potential in a multi-billion dollar market.
%20P%2FS%20Opthea%20Limited&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Opthea-Limited&v=1772551615170 "The graph of the company's future (projected) P/S Opthea Limited")
Future (projected) P/S of the market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company in late-stage clinical development focused on developing new treatments for retinal diseases, such as wet age-related macular degeneration. This chart reflects average future revenue expectations in the ophthalmology sector. It provides an insight into the market perception of Opthea's drug potential.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772551615202 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Opthea Limited is a biopharmaceutical company developing a new drug for the treatment of retinal diseases that lead to vision loss. This chart illustrates general market expectations. The company's success could offer patients a more effective treatment than existing standards, opening the door to the multi-billion dollar ophthalmic drug market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772551615248 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Opthea Limited
This chart shows the revenue of Opthea Limited, a late-stage biopharmaceutical company developing therapies for retinal diseases. At this stage, its revenue, if any, is generated from partnerships rather than sales, reflecting development progress.
Sales of companies in the market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company developing a new drug for the treatment of retinal diseases such as wet age-related macular degeneration. This graph shows the growth of the ophthalmology market. If successful, Opthea's therapy could become a new standard of care, capturing a significant share of one of the largest segments of the pharmaceutical market.
Overall market sales
Opthea Limited is a biopharmaceutical company developing drugs for the treatment of retinal diseases. Its success depends on the results of clinical trials. The overall economic situation, shown in this chart, affects the availability of capital to fund long-term ophthalmology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Opthea Limited
Opthea is an Australian biotech company developing a new drug for the treatment of wet age-related macular degeneration (AMD), the leading cause of blindness in the elderly. The schedule reflects expectations for the success of its drug in the vast ophthalmology market.
%20sales%20of%20the%20company%20Opthea%20Limited&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Opthea-Limited&v=1772551615495 "Schedule of future (projected) sales of the company Opthea Limited")
Future (projected) sales of companies in the market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company developing a new drug for the treatment of retinal diseases such as wet age-related macular degeneration (AMD). Its goal is to offer a more effective treatment than existing standards. This chart shows the forecast for the entire ophthalmology market, where AMD is one of the leading causes of blindness.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772551615524 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Opthea is a late-stage biopharmaceutical company developing a novel treatment for retinal diseases such as wet age-related macular degeneration. Its future depends on the success of clinical trials. This chart, reflecting overall market sentiment, influences investor valuations of the company ahead of a potential blockbuster launch.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772551615563 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Opthea Limited
Opthea is an Australian biotech company developing a new drug to treat retinal diseases such as wet age-related macular degeneration. Being in late-stage clinical trials, it is incurring significant expenses. This chart shows its net losses—an investment in a potential blockbuster in the vast ophthalmology market.
Market segment marginality - Pharma eyes
Opthea is an Australian biopharmaceutical company in late-stage clinical development, developing a new treatment for retinal diseases such as wet age-related macular degeneration. Profitability depends on the success of final trials. This graph reflects the high research costs typical for a company approaching market entry.
Market marginality as a whole
Opthea is an Australian biopharmaceutical company developing new therapies for retinal diseases that lead to vision loss, such as wet age-related macular degeneration. This overall profitability curve is irrelevant to them. Their future depends solely on the results of their key ophthalmology clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Opthea Limited
Opthea is an Australian biotech company developing therapies for retinal diseases. It operates with a small international team managing large clinical trials. This chart reflects its lean, R&D-focused structure.
Share of the company's employees Opthea Limited within the market segment - Pharma eyes
Opthea is an Australian biotech company developing a new drug to treat retinal diseases such as wet age-related macular degeneration. This chart reflects the scale of its global clinical trials. It shows the size of the team required to conduct expensive and complex Phase III trials worldwide.
Number of employees in the market segment - Pharma eyes
Opthea Limited is an Australian biopharmaceutical company in late-stage clinical development focused on treating retinal diseases. This chart shows employment trends in the ophthalmology sector. The growing number of clinical trial specialists here signals the company's approach to bringing a new drug to market for millions of patients.
Number of employees in the market as a whole
Opthea Limited is an Australian biotechnology company developing drugs for the treatment of retinal diseases. Its success depends on global clinical trials and partnerships. Overall economic stability, reflected in this graph, influences the availability of international capital to fund expensive R&D projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Opthea Limited (OPT)
Opthea Limited is a biotech company (Australia/USA) developing a therapy for wet macular degeneration (an eye disease). It is in clinical-stage R&D. The chart shows that the market value per employee is very high. This is typical for biotech, where a small team of scientists is working on a potential blockbuster. The market evaluates not their current work, but the size of the potential market and the likelihood of success in trials.
%20of%20the%20company%20Opthea%20Limited%20(OPT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Opthea-Limited-OPT&v=1772551615854 "Chart of market capitalization per employee (in thousands of dollars) of the company Opthea Limited (OPT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Opthea is a biopharmaceutical company developing treatments for retinal diseases, a leading cause of blindness. Its valuation is based on the potential of its lead drug candidate. This chart demonstrates the high valuation of its research and development efforts, targeting the vast ophthalmology market.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772551615866 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Opthea Limited is an Australian biopharmaceutical company developing drugs to treat retinal diseases. The chart illustrates the assessment of scientific potential. It shows how the market views their lead drug, which has the potential to become a new standard of care for millions of patients with vision loss.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772551615895 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Opthea Limited (OPT)
Opthea is an Australian biotech company in late-stage clinical trials. They are developing a drug to treat wet macular degeneration (the leading cause of blindness in the elderly). This chart shows the enormous costs of final (Phase 3) R&D per employee.
%20Chart%20Opthea%20Limited%20(OPT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Opthea-Limited-OPT&v=1772551615902 "Company Profit Per Employee (in thousands of dollars) Chart Opthea Limited (OPT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Opthea is a late-stage Australian biotech company developing a drug for the treatment of retinal diseases. This loss per employee reflects the high cost of conducting the final, third phase of global clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772551615925 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Opthea Limited is an Australian clinical-stage biotechnology company specializing in the treatment of eye diseases (retinal). It is an R&D company and is not profitable. This chart shows the company's capital burn rate: operating loss per research team.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772551615955 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Opthea Limited (OPT)
Opthea is a biopharmaceutical company developing drugs for the treatment of retinal diseases. This chart reflects the progress of its lead candidate commercialization. Revenue per employee growth will depend on the success of late-stage clinical trials and a potential partnership with a major pharmaceutical company to bring the product to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Opthea-Limited-OPT&v=1772551615994 "Sales chart per company employee Opthea Limited (OPT)")
Sales per employee in the market segment - Pharma eyes
Opthea is an Australian biotech company developing drugs to treat wet macular degeneration (AMD), the leading cause of blindness in the elderly. This chart shows how productive their R&D team is. It measures revenue (from partnerships) per scientist, reflecting the value of their research in ophthalmology.
Sales per employee for the market as a whole
Opthea (OPT) is an Australian late-stage biopharmaceutical company developing a treatment for wet macular degeneration (an eye disease). The company is preparing for commercialization. This chart illustrates its pre-launch readiness: a large team of specialists is focused on R&D and launch preparation, which is an investment in future revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Opthea Limited (OPT)
Opthea Limited is an Australian biotech company developing a drug for the treatment of wet macular degeneration (AMD). This chart shows bearish bets. Investors are betting that its drug will fail to outperform existing blockbusters like Eylea in head-to-head clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Opthea-Limited-OPT&v=1772551616070 "Short Shares Chart for the Company Opthea Limited (OPT)")
Shares shorted by market segment - Pharma eyes
Opthea Limited is a biopharmaceutical company developing new treatments for retinal diseases. They focus on the competitive ophthalmology market. This indicator shows the overall volume of short bets across the sector. It helps understand how skeptical the market is overall about new drugs in this field, anticipating intense competition or challenges in clinical trials for the entire industry.
Shares shorted by the overall market
Opthea (OPT) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like OPT in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Opthea Limited (OPT)
This oscillator for Opthea is a binary bet on the treatment of wet macular degeneration (an eye disease). The company is attempting to unseat the giant Eylea with its drug. "Overheating" (above 70) occurs in anticipation of Phase 3 data. A failure in this key study or safety concerns would immediately send the stock plummeting (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Opthea-Limited-OPT&v=1772551616129 "RSI 14 indicator chart for the company's stock Opthea Limited (OPT)")
RSI 14 Market Segment - Pharma eyes
Opthea (OPT) is an Australian biotech company developing a new drug for the treatment of wet macular degeneration (AMD), the leading cause of blindness in the elderly. This chart tracks overall sentiment in the Pharma/Ophthalmology sector. It helps investors understand whether the entire biotech segment is overhyped or oversold.
RSI 14 for the overall market
For Opthea, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OPT (Opthea Limited)
Opthea (OPT) is an Australian biotech developing a drug (sozinibercept) for the treatment of wet AMD, a multibillion-dollar market for retinal diseases. This chart shows the average target price. It reflects analysts' confidence in the success of its key Phase 3 trials and its ability to compete with blockbusters (Eylea) in ophthalmology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OPT-Opthea-Limited&v=1772551616205 "A chart showing analyst consensus forecasts for the expected stock price. OPT (Opthea Limited)")
The difference between the consensus estimate and the actual stock price OPT (Opthea Limited)
Opthea (OPT) is an Australian biotech betting on a "combo" in ophthalmology. Their drug (OPT-302) is expected to *improve* the standard of care for wet AMD (an eye disease). This chart shows the difference between the market valuation and the consensus estimate. It indicates whether experts believe their Phase 3 R&D binary outcome will be successful.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OPT-Opthea-Limited&v=1772551616231 "A chart showing the difference between the consensus forecast and the actual stock price. OPT (Opthea Limited)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Opthea, an Australian biotech, is going all-in with its lead drug (OPT-302) for wet AMD (an eye disease), attempting to outperform Eylea. This chart displays analyst expectations for the entire ophthalmic pharmaceutical sector. It shows whether experts believe in the success of their R&D competitors.
Analysts' consensus forecast for the overall market share price
Opthea (OPT) is an Australian biopharmaceutical company. They are developing a drug (OPT-302) for the treatment of wet AMD (retinal degeneration), attempting to improve the standard of care currently held by giants Regeneron and Roche. This chart shows the overall risk appetite, reflecting the market's willingness to fund the R&D race in ophthalmology's hottest topic.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Opthea Limited
Opthea is an Australian biotech eye-hunter. Their signature product is OPT-302, a new drug (in R&D) that (they claim) improves existing ones (Eylea) for the treatment of wet macular degeneration (AMD). This chart is a pure indicator of their R&D. Its dynamics are all or nothing, depending entirely on their (very risky) Phase 3 clinical trial data.
AKIMA Market Segment Index - Pharma eyes
Opthea (OPT) is an Australian eye pharma company. They develop drugs to treat wet age-related macular degeneration (AMD), the leading cause of blindness in the elderly. It's a huge market. This chart compares their composite index to the sector, showing how their R&D approach to AMD compares to others.
The AKIM Index for the overall market
Opthea is a biopharmaceutical company developing Sozinibercept for the treatment of wet AMD (an eye disease) in combination with standard treatment. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this Australian late-stage clinical company compares to overall economic trends.
